{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-25-000021","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2025-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.453315+00:00","generated_at":"2026-05-27T07:03:28.614175+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Praxis reports $470M cash, NDA plans for ulixacaltamide in 2025, and UCB option exercise for KCNT1","bullets":["Cash, cash equivalents and marketable securities ~$470M at Dec 31, 2024; runway into 2028.","Interim analysis of Essential3 Study 1 for ulixacaltamide in essential tremor expected Q1 2025; NDA filing planned for 2025.","UCB exercised option to license KCNT1 small molecule; Praxis eligible for up to ~$100M milestones plus tiered royalties.","RADIANT (vormatrigine) topline in H1 2025; POWER1 (vormatrigine) topline by year-end 2025.","EMBOLD cohort 2 for relutrigine on track with NDA filing expected in 2026; third RPDD received for Dravet Syndrome."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-25-000021","json":"https://secwatch.observer/filing/0001689548-25-000021.json","markdown":"https://secwatch.observer/filing/0001689548-25-000021.md","text":"https://secwatch.observer/filing/0001689548-25-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000021/0001689548-25-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000021/prax-20250112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T07:03:28.614175+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}